Lumley CJ, et al. - To define the impact of post-diagnosis aspirin use on survival in veterans with head and neck squamous cell carcinoma, investigators examined 584 veterans with head and neck squamous cell carcinoma treated at the Washington DC VA Medical Center between 1995 and 2015. They included oropharynx (n = 143), larynx (n = 105), oral cavity (n = 62), and hypopharynx (n = 19) as the primary subsites. About 25.5% were aspirin users. They noted significantly better 3-year overall survival (OS) and disease-specific survival (DSS) (78.6% and 88.1%) in aspirin users when compared to nonaspirin users (OS: 55.9% and DSS: 70.2%). Independent association of aspirin use was reported with improved survival on multivariate analysis.